Sumitomo Dainippon Pharma Co., Ltd. provided financial guidance for the year ending March 31, 2022. For the period, the company expected Net sales of JPY 554,000 million, Operating profit of JPY 55,000 million, Net profit attributable to owners of parent of JPY 37,000 million and EPS of JPY 93.13.